YIH
SGMT icon

Y-Intercept (HK)’s Sagimet Biosciences SGMT Stock Holding History

Y-Intercept (HK)’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-96,888
Closed -$331K – 1755
2024
Q2 		$331K Buy
+96,888
New +$444K 0.02% 995

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Y-Intercept (HK)'s SGMT Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Sagimet Biosciences (SGMT) in Q3 2024, closing a stake of 96,888 shares — an estimated $331K sold.

Y-Intercept (HK) first reported a position in SGMT in Q2 2024 and held it in 1 quarter. The position peaked at $331K in Q2 2024. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Sagimet Biosciences position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 96,888 Sagimet Biosciences shares in Q3 2024, an estimated $331K.
  • Y-Intercept (HK) first reported a position in Sagimet Biosciences in Q2 2024 and held it in 1 quarter.
  • Y-Intercept (HK)'s Sagimet Biosciences position peaked at $331K in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.